Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target resistance mechanisms in hematologic and solid malignancies, today announced the acquisition of Ness Therapeutics Inc (Ness) in an all-equity transaction. Ness is developing best-in-class PTPN2 inhibitors providing an immuno-oncological therapy with an improved safety and tolerability profile.
Read the full article: Eilean Therapeutics Acquires Ness Therapeutics //
Source: https://www.prnewswire.com/news-releases/eilean-therapeutics-acquires-best-in-class-non-clinical-ptpn2-program-302076756.html